News & Updates
Filter by Specialty:
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
Treatment with nivolumab plus ipilimumab in the frontline setting provides clinically meaningful overall survival (OS) benefit compared with lenvatinib or sorafenib to patients with unresectable hepatocellular carcinoma (HCC) who were naive to systemic therapy, according to data from the phase III CheckMate 9DW study presented at ASCO GI 2025.
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
25 Feb 2025
Aspirin use lowers risk of common GI cancers
Taking aspirin contributes to a reduced risk of several gastrointestinal (GI) malignancies, such as colorectal cancer (CRC), liver cancer, stomach cancer, and pancreatic cancer, as shown by the results of a 20-year study presented at ASCO GI 2025. However, no association is seen with most non-GI cancers.
Aspirin use lowers risk of common GI cancers
24 Feb 2025
SC infliximab dose escalation restores efficacy, elicits rapid response in IBD
A retrospective analysis has shown that increasing the dose of subcutaneous infliximab (CT-P13 SC) from 120 to 240 mg Q2W in patients with inflammatory bowel disease who initially responded but subsequently lost response leads to improved clinical efficacy over an extended period.